Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2010
02/09/2010CA2430273C Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them
02/09/2010CA2422496C Disinfectant comprising an amine and an alkanolamine
02/09/2010CA2418224C Pharmaceutical composition
02/09/2010CA2416792C Crystalline and pure modafinil, and process of preparing the same
02/09/2010CA2414921C Use of diclofenac for treatment of burns
02/09/2010CA2413061C Serine protease inhibitors
02/09/2010CA2410647C Substituted phenylpropanoic acid derivatives
02/09/2010CA2409975C Blister package for topiramate tablets
02/09/2010CA2407112C Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents
02/09/2010CA2405819C Conjugated linoleic acid powder
02/09/2010CA2403756C Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
02/09/2010CA2403670C Multiparticulate drug form comprising at least two differently coated pellet forms
02/09/2010CA2392033C Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
02/09/2010CA2389688C A method of microencapsulation
02/09/2010CA2386297C Bicyclic amino acids as pharmaceutical agents
02/09/2010CA2378976C Method of controlling body temperature while reducing shivering
02/09/2010CA2375201C Crystal of (r)-lansoprazole
02/09/2010CA2370714C Bacterial ghosts as carrier and targeting vehicles
02/09/2010CA2363934C Oligomers substituted by phosphite ester, phosphonic acid,or carbaborane functions and the corresponding pna monomers
02/09/2010CA2354762C Novel therapeutic application of low molecular weight heparin
02/09/2010CA2353612C Boron neutron capture therapy using pre-targeting methods
02/09/2010CA2349715C Electrotransport device including a compatible antimicrobial agent
02/09/2010CA2338546C Particle-forming compositions containing fused pyrrolocarbazoles
02/09/2010CA2315646C Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
02/09/2010CA2311670C Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
02/09/2010CA2308274C Methods for modulating macrophage proliferation using polyamine analogs
02/09/2010CA2294276C Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
02/09/2010CA2294274C Compositions and methods for reversibly increasing permeability of biomembranes
02/09/2010CA2291065C Raf kinase inhibitors
02/09/2010CA2287469C Interactive system for presenting and eliminating substances
02/09/2010CA2287370C Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
02/09/2010CA2286614C Plant extracts for the treatment of increased bone resorption
02/09/2010CA2274201C Di-or triaza-spiro[4,5]decane derivatives
02/09/2010CA2268403C Anthranilic acid derivatives as multi drug resistance modulators
02/09/2010CA2235810C Senescent cell-derived inhibitors of dna synthesis
02/09/2010CA2218369C Transdermal electrotransport delivery of fentanyl and sufentanil
02/09/2010CA2205910C Plasmids suitable for il-2 expression
02/09/2010CA2201863C Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
02/09/2010CA2192092C Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
02/09/2010CA2150933C Glaucoma treatment
02/04/2010WO2010014990A2 Method of promoting neurogenesis by modulating secretase activities
02/04/2010WO2010014953A1 Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
02/04/2010WO2010014943A2 Methionine analogs and methods of using same
02/04/2010WO2010014933A2 Psma-binding agents and uses thereof
02/04/2010WO2010014930A2 Therapeutic agents
02/04/2010WO2010014889A2 Nitro fatty acids as regiomers and related mimetics
02/04/2010WO2010014888A2 Methods of enhancing opsonophagocytosis in response to a pathogen
02/04/2010WO2010014883A2 Azacitidine process and polymorphs
02/04/2010WO2010014841A1 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
02/04/2010WO2010014836A2 Tgr5 modulators and methods of use thereof
02/04/2010WO2010014819A1 Accelerated therapy
02/04/2010WO2010014798A2 Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same
02/04/2010WO2010014784A2 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
02/04/2010WO2010014771A1 Romazarit for treating metabolic diseases
02/04/2010WO2010014766A1 Low dosage forms of risedronate or its salts
02/04/2010WO2010014765A1 Low dosage forms of risedronate or its salts
02/04/2010WO2010014758A1 Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
02/04/2010WO2010014744A1 Inhibitors of hepatitis c virus infection
02/04/2010WO2010014739A2 Heterocyclic modulators of tgr5
02/04/2010WO2010014728A1 Use of tetrakis (n-alkylpyridinium) -porphyrin derivatives for killing microbes or preventing growth
02/04/2010WO2010014727A1 Pharmaceutical compositions and methods for producing low impurity concentrations of the same
02/04/2010WO2010014687A1 Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity
02/04/2010WO2010014676A1 Composition and method for treatment of mrsa
02/04/2010WO2010014661A1 Novel method
02/04/2010WO2010014658A1 Thermochemical ablation system using heat from delivery of electrophiles
02/04/2010WO2010014617A1 Heat shock protein 90 inhibitor dosing methods
02/04/2010WO2010014613A2 Treating various disorders using trkb agonists
02/04/2010WO2010014611A1 Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
02/04/2010WO2010014595A2 Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
02/04/2010WO2010014593A1 Chemical compounds and uses
02/04/2010WO2010014592A1 Selective inhibition of polyglutamine protein expression
02/04/2010WO2010014585A1 Pkc-activating compounds for the treatment of neurodegenerative diseases
02/04/2010WO2010014554A1 Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
02/04/2010WO2010014552A1 Vasoconstriction compositions and methods of use
02/04/2010WO2010014516A1 Nitro derivatives of furasemide and their use as diuretics
02/04/2010WO2010014361A1 Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties
02/04/2010WO2010014285A1 Compositions including clavulanic acid and related methods of use
02/04/2010WO2010014280A1 Pyrazinone modulator of corticotropin-releasing factor receptor activity
02/04/2010WO2010014263A1 Methods and compositions involving (s)-bucindolol
02/04/2010WO2010014253A2 Ant4 inhibitor compounds and methods of use thereof
02/04/2010WO2010014250A1 Prediction of cancer therapy based on cathespin b levels
02/04/2010WO2010014240A2 Novel bioactive small molecules derived from sea sponges
02/04/2010WO2010014234A1 Pharmaceutical compositions and methods for stabilizing the same
02/04/2010WO2010014229A1 Buprenorphine analogs
02/04/2010WO2010014220A1 Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
02/04/2010WO2010014199A2 Uses of morelloflavone
02/04/2010WO2010014184A1 Parenteral treatment with statins
02/04/2010WO2010014142A1 Laidlomycin compositions and methods
02/04/2010WO2010014141A1 Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
02/04/2010WO2010014134A1 Compounds and pharmaceutical compositions for the treatment of viral infections
02/04/2010WO2010014117A1 Drug carriers
02/04/2010WO2010014076A1 Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist
02/04/2010WO2010014025A1 Administration regime for nitrocatechols
02/04/2010WO2010014022A1 A process for the preparation of imatinib
02/04/2010WO2010014015A1 Tablet manufacturing method
02/04/2010WO2010013987A2 Extraction method for increasing liquiritigenin content in glycyrrhizae radix et rhizoma or glycyrrhizae radix extract
02/04/2010WO2010013978A2 Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity
02/04/2010WO2010013975A2 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate
02/04/2010WO2010013969A2 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt
02/04/2010WO2010013925A2 Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
1 ... 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 ... 7860